Hormonal status of patients after surgical treatment of fibrocystic mastopathy
Keywords:mastopathy, postoperative rehabilitation, mastodynia, Mastodynon
The purpose of the study was to investigate the efficacy of Mastodynon® in terms of indications in elevated doses versus the standard dose.
Materials and methods. Data were analyzed for 60 patients after surgical treatment of fibrocystic mastopathy. Depending on the postoperative therapy received by the patients, they were divided into three equal groups. Patients of Group I were observed in accordance with the standards established in mammal practice and did not receive special agents that affect hormonal homeostasis. Patients of Group II in addition to observation received Mastodynon® (1 tablet or 30 drops 2 times a day) for 6 months. Patients of Group III were given for a postoperative rehabilitation Mastodynon® in a double dose (2 tablets or 60 drops 2 times a day) for 6 months.
Results. Surgical treatment without conservative therapy eliminates organic changes in the breast, but hormonal disorders that have led to pathologic and histological changes in the tissues of breast continue to exist for a long time and can lead to repeated nodal formations. In group І, 25% of patients within 2 years performed repeated sectoral resections on recurrence of nodule formation. The use of Mastodynon® in standard doses (group II) for postoperative rehabilitation contributes to a significant improvement in hormonal homeostasis (normalization of prolactin, estradiol and progesterone levels), a 24.7 mm decrease in the degree of cyclic mastodynia according to the visual analog scale (VAS), and the improvement of ultrasound scan picture of breast in 75% of patients. The most pronounced effect of this rehabilitation approach after the surgical treatment phase was noted for the use of Mastodynon® in double doses (2 tablets or 60 drops 2 times a day) in Group III. In these patients, the degree of reduction of cyclic mastodynia was 30 mm for VAS and positive changes in the tissues of breast were noted in 85% of patients.
Conclusion. Despite the presence of short-term side effects and rapid rebounding in the double-dose Mastodynon® group, our study showed better results than standard doses, faster and more stable therapeutic effect. Taking into account the results obtained, it can be argued that the use of high doses of Mastodynon® may be recommended to patients for the treatment of mastopathy.
Smolanka, I.I., Ljashenko, A.О. “Fibrocystic breast disease.” Women’s Doctor 1 (2007): 16.
Zaitsev, V.F., Nikolaenko, T.A., Sugak, S.V. “Surgeon tactic at the nodal lesions of breast.” Actual problems of clinical medicine MN (1999): 35–6.
Vysotskaya, I.V., Letyagin, V.P., Kim, E.A. “Dishormonal mammary dysplasia.” Mammology 2 (2006): 9–12.
Andreeva, E.N., Ledneva, E.V. “Key aspects of the etiology and pathogenesis of fibrocystic breast disease.” Obstetrics and Gynecology 6 (2002): 7–9.
Tagieva, T.T., Volobuev, A.I. “Using Mastodynon in women with fibrocystic breast disease.” Health of Ukraine 5 (2002).
Wuttke, W., Jarry, H., Christoffe, V., et al. “Chaste tree (Vitex agnus-castus) – Pharmacology and clinical indications.” Phytomedicine 10 (2003): 348–57.
Copyright (c) 2018 Ю. Я. Присташ
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.